Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Chronic Spontaneous Urticaria
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

Article

October 1, 2003

Risks of TNF-α Blockers

Montreal - Drugs that block tumor necrosis factor alpha are showing great promise for the treatment of moderate to severe psoriasis, a condition that causes sufferers a good deal of misery and that can be frustratingly resistant to many treatments. However, the high potency comes with a tradeoff. Research indicates that blocking TNF-a may place patients at a higher risk for serious infections, notably tuberculosis.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!